Axsome's Alzheimer's Launch Drives Record Prescriptions, Pipeline Advances
Record Auvelity Prescriptions on Alzheimer's Launch Auvelity prescriptions hit a record ~23,500 weekly, with new-to-brand scripts reaching 3,800 as the Alzheimer's agitation launch grows. Patients 65+ now make up 31% of new scripts, up from 19%, showing strong demand and supporting the $8 billion peak-sales outlook.
This is the core demand driver behind the stock's recent move and the biggest new commercial catalyst.
Pipeline Advances with AXS-12 PDUFA and Phase III Start AXS-12 for cataplexy got a May 1, 2027 PDUFA date, and Axsome dosed the first patient in a Phase III study of AXS-05 for smoking cessation. Management targets roughly one new drug filing per year through 2030, expanding the pipeline beyond current products.
Shows new growth opportunities beyond Auvelity, which supports the long-term investment case.
Strong Q2 Revenue and Path to Cash Flow Positive Q2 net product revenue rose 46% to $218 million, led by Auvelity and Sunosi. Management expects revenue to grow faster than expenses, with $320 million cash funding operations into cash flow positivity, reducing financing risk.
Financial strength and profitability path are key to sustaining investor confidence.
Analyst Backing and New Clinical Data B. Riley named Axsome a top biotech pick with a $300 price target ahead of Q3 earnings. New clinical data in depression and Alzheimer's agitation were presented, adding detail to the pipeline and supporting future regulatory interactions.
Analyst endorsement and data reinforce the growth narrative and can attract investors.